Filter By Category
Archives
Share on -
CUGRASTOMIG
Generic Name: CUGRASTOMIG
ABSTRACT -
Cugrastomig is an investigational bispecific antibody targeting immune checkpoints LAG-3 and PD-1, under study for solid tumors and hematologic malignancies such as gastric cancer and refractory Hodgkin lymphoma.
DOSAGE -
No approved dosage has been established. Use is limited to clinical-trial protocols with route, infusion schedule, premedication, and toxicity-management rules specified by the study.
SIDE EEFECTS -
The full adverse-event profile is not established. Expected checkpoint-inhibitor risks include fatigue, rash/pruritus, diarrhea or colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, infusion reactions, and infection complications from immunosuppression used to treat immune toxicity.
ALLERGIC REACTIONS -
Infusion reactions, hypersensitivity, or anaphylaxis may occur. Monitor during and after infusion and treat fever, chills, rash, bronchospasm, hypotension, angioedema, or anaphylaxis promptly.
DRUG INTERACTIONS-
Systemic corticosteroids or immunosuppressants may reduce antitumor immune activity but may be necessary to manage immune-related adverse reactions. Combination immunotherapies, chemotherapy, targeted therapy, or live vaccines require protocol-specific assessment.
PREAUTONS–
Trial use only. Monitor immune-mediated adverse events with baseline and periodic liver, renal, thyroid/endocrine, pulmonary, and gastrointestinal assessment. Use caution in autoimmune disease, organ transplant recipients, pregnancy, and lactation.
WARNINGS –
- Immune-related adverse reactions may be severe or fatal. No approved indication or standard dose.
Share on -
. Developed by